Suppr超能文献

接受生物治疗的炎症性肠病患者的反应和疾病进程的预测因素:丹麦 IBD 生物库项目:一项多中心前瞻性队列研究方案。

Predictors of response and disease course in patients with inflammatory bowel disease treated with biological therapy-the Danish IBD Biobank Project: protocol for a multicentre prospective cohort study.

机构信息

Gastro Unit, Medical Division, Hvidovre University Hospital, Hvidovre, Denmark

Gastro Unit, Medical Division, Hvidovre University Hospital, Hvidovre, Denmark.

出版信息

BMJ Open. 2020 Feb 25;10(2):e035756. doi: 10.1136/bmjopen-2019-035756.

Abstract

INTRODUCTION

Inflammatory bowel diseases (IBDs) are chronic diseases of unknown cause characterised by a progressive and unpredictable disease course. In the last decade, biological treatment has become a cornerstone in the treatment of IBD. However, one-in-three-to-four patients do not respond to first-line biological agents and another third of patients see their response diminish over time. This highlights an unmet need for optimising the use of biologicals and the prediction of treatment response. Considering the multifaceted nature of IBD, we hypothesise that multiomics profiling of sequential samples from single patients could facilitate the discovery of predictive biomarkers of response to biological therapy and disease course.

METHODS

This is a multicentre prospective cohort study which will enrol 840 biological-naïve patients with IBD who initiate biological therapy in a 3-year period. Primary outcomes are the occurrence of primary non-response (evaluated at weeks 14-16) and loss of response (evaluated during entire follow-up in patients who obtain partial or full response after induction period). Each patient will be followed up for their clinical data for at least 1 year or till the end of study period (up to 4 years). Blood and stool samples will be collected sequentially during the first year of biological treatment. Intestinal tissue will be sampled after 1 year of treatment and whenever an endoscopy is performed. Samples will undergo transcriptomic, proteomic and microbial DNA analyses. Omics data will be integrated with clinical data to identify a panel of predictive biomarkers of response to biological therapy and disease behaviour in patients with IBD.

ETHICS AND DISSEMINATION

Ethical approval has been obtained from the Danish Ethics Committee (H-18064178). Inclusion is ongoing at three study centres and will be initiated in two additional centres. Both positive and negative study results will be disseminated through peer-reviewed journals according to Strengthening the Reporting of Observational Studies in Epidemiology guidelines, as well as presented at international conferences.

摘要

介绍

炎症性肠病(IBD)是一种病因不明的慢性疾病,其病程呈进行性和不可预测性。在过去十年中,生物治疗已成为治疗 IBD 的基石。然而,三分之一到四分之一的患者对一线生物制剂没有反应,另有三分之一的患者随着时间的推移其反应会减弱。这凸显了优化生物制剂使用和预测治疗反应的需求。考虑到 IBD 的多方面性质,我们假设对来自单个患者的连续样本进行多组学分析可能有助于发现对生物治疗和疾病过程有反应的预测性生物标志物。

方法

这是一项多中心前瞻性队列研究,将在 3 年内招募 840 名接受生物治疗的 IBD 初治患者。主要结局是发生原发性无应答(在诱导期后 14-16 周评估)和应答丧失(在诱导期后整个随访期间评估对获得部分或完全应答的患者)。每个患者将至少随访 1 年或直至研究结束(最长 4 年),以获取其临床数据。在接受生物治疗的第一年期间,将连续采集血液和粪便样本。在接受治疗 1 年后,以及每次进行内镜检查时,将采集肠道组织样本。样本将进行转录组、蛋白质组和微生物 DNA 分析。将整合组学数据与临床数据,以确定一组预测 IBD 患者对生物治疗和疾病行为有反应的生物标志物。

伦理和传播

丹麦伦理委员会已批准该研究(H-18064178)。该研究正在三个研究中心进行纳入,另外两个中心也将开始纳入。无论研究结果是阳性还是阴性,都会根据《加强观察性研究的报告:流行病学指南》在同行评审期刊上发表,并在国际会议上展示。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31dd/7045223/32a3f8405343/bmjopen-2019-035756f01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验